Skip to main content

Podcast: Teva Seeks Label Change for Azilect

This fall, The FDA recommended that Teva Neuroscience’s drug rasagiline, brand name Azilect, should not be granted status “to slow the clinical progression of PD.”  In this podcast, Dave Iverson speaks with MJFF’s Brian Fiske about what this recommendation could mean for those living with PD.

To read more about the FDA's recommendation, check out this Fox Foundation News in Context with Parkinson's Progression Markers Initiative (PPMI) Principal Investigator Dr. Ken Marek.

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.